

Anti-Complement C5 Antibody (Ravulizumab)

Introduction

Ravulizumab (ALXN1210) is a humanized monoclonal antibody that specifically binds to human complement protein C5 with high affinity. Ravulizumab is used in the study of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis.

Product parameters

Alternative Names	Ultomiris, ravulizumab-cwvz, ALXN 1210
Target Accession	P01031
Target	Complement C5
CAS number	1803171-55-2
Molecular Weight	145.8 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG2SA
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human C5 His at 2 ug/mL can bind Anti-Complement C5 Antibody (Ravulizumab), EC50=0.00552 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APEx BIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

